Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | RXRB | P28702 | 2/20 | 0.43 |
| ▸ | RXRG | P48443 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3566072 | 0.88 | PPARD (0.50) | PPARDPPARARXRARXRBRXRG | |
| SCHEMBL491528 | 0.81 | RXRA (0.47) | PPARDPPARARXRARXRBRXRG | |
| SCHEMBL491476 | 0.79 | PPARD (0.48) | PPARDPPARARXRARXRBRXRG | |
| SCHEMBL477855 | 0.79 | PSEN1 (0.60) | PPARDPPARARXRARXRBRXRG | |
| SCHEMBL3655356 | 0.78 | PPARD (0.44) | PPARDPPARARXRARXRBRXRG | |
| SCHEMBL491285 | 0.78 | PPARD (0.49) | PPARDPPARARXRARXRBRXRG | |
| SCHEMBL3651171 | 0.76 | RXRA (0.54) | PPARDPPARARXRARXRBRXRG | |
| SCHEMBL11988716 | 0.76 | PPARD (0.43) | PPARDPPARARXRARXRBRXRG | |
| SCHEMBL5129196 | 0.74 | RXRA (0.65) | PPARDPPARARXRARXRBRXRG | |
| SCHEMBL1045007 | 0.73 | MAPT (0.56) | PPARAPPARGMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825160-B2 | such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity | CELLZOME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | CELLZOME AG (DE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | BACE1, BACE2, APP | PPARD 455/4885PPARA 327/4885RXRA 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.